- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors
May 31st 2020, 2:35am
Brian A. Van Tine, MD, PhD, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.
Tislelizumab Frontline Combos Extend PFS in Squamous NSCLC
May 31st 2020, 2:00am
Combining the anti–PD-1 agent tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer.
Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer
May 31st 2020, 1:37am
The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.
Cabozantinib/Atezolizumab Combo Shows Promise in Previously Treated Urothelial Carcinoma
May 31st 2020, 1:08am
The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated promising objective responses in patients with urothelial carcinoma who progressed after receiving platinum-containing chemotherapy.
Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL
May 31st 2020, 1:05am
Axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Trastuzumab Deruxtecan Shows Promising Clinical Activity in CRC and Gastric/GEJ Tumors
May 31st 2020, 12:47am
Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer, as well as in those with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Teclistamab Appears Safe at All Doses for Relapsed/Refractory Myeloma Treatment
May 31st 2020, 12:29am
Teclistamab (JNJ-64007957) appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma.
Apalutamide Plus ADT Leads to Significantly Improved Outcomes in Nonmetastatic CRPC
May 31st 2020, 12:08am
Results from the phase III SPARTAN trial showed that apalutamide plus androgen deprivation therapy significantly improved overall survival when compared with ADT plus placebo in patients with nonmetastatic castration-resistant prostate cancer.
KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL
May 30th 2020, 11:57pm
The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial.
Encorafenib/Binimetinib Combo Continues to Show Survival Benefits in BRAF V600-Mutant Melanoma
May 30th 2020, 11:23pm
The combination of encorafenib and binimetinib demonstrated continuing benefit in overall survival and progression-free survival for patients with BRAF V600–mutant melanoma.
CC-92480 Shows Encouraging Efficacy in First-in-Human Study for R/R Multiple Myeloma
May 30th 2020, 11:05pm
An ongoing study of CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma.
Update Sustains OS Benefit With Encorafenib/Cetuximab Regimens in BRAF+ mCRC
May 30th 2020, 10:14pm
The latest results from the phase 3 BEACON CRC study continued to show an overall survival benefit for encorafenib plus cetuximab with or without binimetinib compared with cetuximab plus irinotecan-containing regimens in patients with BRAF V600E–mutated metastatic colorectal cancer.
Diagnostic Performance of PSMA-Targeted PET Tracer Excels in Relapsed Prostate Cancer
May 30th 2020, 9:51pm
Imaging with 18F-DCFPyL-PET/CT outperformed that of standard imaging modalities—such as bone scan, CT, MRI, and FDG PET—in patients with biochemically relapsed prostate cancer.
AMG 330 Shows Promise in Treating Relapsed/Refractory AML
May 30th 2020, 9:40pm
Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia, with cytokine release syndrome as the most frequent and expected adverse event.
5-Year Follow-Up of COMBI-AD Confirms Long-Term RFS Benefit With Dabrafenib/Trametinib in BRAF+ Melanoma
May 30th 2020, 9:12pm
Findings from a 5-year analysis of the phase 3 COMBI-AD trial validated the long-term benefit of adjuvant dabrafenib and trametinib in patients with resected, stage III BRAF V600E/K-mutant melanoma.
Pembrolizumab Doubles 24-Month PFS2 in PD-L1 HNSCC
May 30th 2020, 8:54pm
Treatment with pembrolizumab improved progression-free survival after subsequent therapy for patients with PD-L1–positive, relapsed/refractory head and neck squamous cell carcinoma.
AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors
May 30th 2020, 7:36pm
AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.
Updated AVANOVA2 Survival Data Further Support Niraparib Plus Bevacizumab in Recurrent Ovarian Cancer
May 30th 2020, 7:24pm
Clinical outcomes in patients with recurrent ovarian cancer who were treated with niraparib plus bevacizumab were significantly improved when compared with niraparib alone.
HERO Trial Suggests Relugolix to Become New Standard for T-Suppression in Advanced Prostate Cancer
May 30th 2020, 6:58pm
Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks in patients with advanced prostate cancer.
Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma
May 30th 2020, 5:47pm
Treatment with pembrolizumab induced a 4.9-month progression-free survival benefit over brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma.